We have been awarded the “NEDO PCA” grant from the New Energy and Industrial Technology Development Organization (NEDO). The grant application was supported by the venture capital firm Miyako Capital. The grant will enable us to further enhance our proprietary RNA-targeted small molecule drug discovery platform. By advancing the platform from hit compound identification to lead compound development, we aim to establish a strong foundation that accelerates research and development in this field.
About Miyako Capital
Miyako Capital is an independent venture capital firm that invests in R&D-driven startups leveraging cutting-edge intellectual assets from academia and research institutions, including Kyoto University. Through its support for industry-academia collaboration and initiatives that drive the societal implementation of research outcomes, Miyako Capital is dedicated to fostering next-generation industries and innovations.
About xFOREST Therapeutics
xFOREST Therapeutics Co., Ltd. is a Kyoto-based biotechnology company engaged in the research and development of RNA-targeted small-molecule medicines. Building on its proprietary RNA structure analysis technology, xFOREST discovers selective small molecules for RNA targets that protein-first discovery cannot reach, and advances them into drug programs with partners.